In addition, NPC1L1 was examined in MCs, MPCs, and RCs by Western blotting, which demonstrated that protein levels of NPC1L1 were significantly increased in MPCs and returned back to their basal levels in RCs, consistent with the reversible drug‐resistant capacity of MDR cancer cells during the treatment (Fig 2F). Here, NPC1L1 is linked to cancer.